



# PUM1 represses CDKN1B translation and contributes to prostate cancer progression

Xin Li<sup>1,△</sup>, Jian Yang<sup>1,2,△</sup>, Xia Chen<sup>1</sup>, Dandan Cao<sup>1</sup>, Eugene Yujun Xu<sup>1,3,✉</sup>

<sup>1</sup>State Key Laboratory of Reproductive Medicine, Nanjing Medical University, Nanjing, Jiangsu 211166, China;

<sup>2</sup>Department of Urology, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 211166, China;

<sup>3</sup>Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.

**Supplementary Table 1** Clinical characteristics of the prostate cancer cohort

Characteristics	Patients (n=20)
Age (years)	
Mean±SD	70.5±4.59
Median (range)	68 (61–76)
Preoperative PSA (ng/mL)	
Mean±SD	12.33±5.42
Median (range)	11.9 (5.7–24.5)
Pathological stage (n)	
pT2	15
pT3	9
Gleason score (n)	
7	16
>7	4

**Supplementary Table 2** Primers used for realtime RT-PCR

Human genes	Primer sequence (5'→3')
PUM1	Forward: TGAATCCAGCAAAGATGGACC
	Reverse: ATACTCCACCATGCTAACGCC
CDKN1B	Forward: AACGTGCGAGTGTCTAACGG
	Reverse: CCCTCTAGGGGTTTGTGATTCT
ACTB	Forward: CATGTACGTTGCTATCCAGGC
	Reverse: CTCCTTAATGTCACGCACGAT

<sup>△</sup>These authors contributed equally to the work.

<sup>✉</sup>Corresponding author: Eugene Yujun Xu, Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA. E-mail: [e-xu@northwestern.edu](mailto:e-xu@northwestern.edu).

Received: 15 April 2021; Revised: 20 May 2021; Accepted: 25 May 2021; Published online: 16 July 2021

CLC number: R737.25, Document code: A

The authors reported no conflict of interests.

This is an open access article under the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.